Evaluation of the immunogenicity of a recombinant vaccine against hepatitis B containing S and pre-S2 sequences using two different schedules.
The immunogenicities of hepatitis B virus vaccines containing S and pre-S2 regions were compared using two different schedules of immunization (A: 0-1-2-12 months and B: 0-1-6 months). Two hundred males and females aged 17-22 years were vaccinated with 20 micrograms per dose. The follow-up period was extended up to 13 months. One month after the booster dose anti-HBs were detected in 98.9% of those vaccinated with schedule A and 100% of those vaccinated with schedule B. Geometric mean titres (GMT) of anti-HBs were significantly higher with schedule A than schedule B, reaching GMT of 16269.7 mIU ml-1 and 4372.4 mIU ml-1, respectively, one month after the booster dose. Seroconversion rates for the anti-pre-S2 antibodies one month after the booster dose were 89.4% for schedule A and 76.6% for schedule B. GMT were 157.8 mIU ml-1 and 67.5 mIU ml-1, respectively. We conclude that both vaccines elicit high titres of anti-HBs and anti-pre-S2 antibodies. Immunity lasts longer in schedule A than in schedule B.
Gizaris
V
V
Nursing School, University of Athens.
Roumeliotou
A
A
Ktenas
E
E
Papoutsakis
G
G
Papaevangelou
G
G
D000293:Adolescent; D000328:Adult; D004275:DNA, Ribosomal / Q000276:immunology*; D004334:Drug Administration Schedule; D005069:Evaluation Studies as Topic; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000032:analysis / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology* / Q000494:pharmacology; D006801:Humans; D007114:Immunization; D008297:Male; D011498:Protein Precursors / Q000032:analysis; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology* / Q000494:pharmacology
D004275:DNA, Ribosomal; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D011498:Protein Precursors; C069095:TGP 943 vaccine; D014614:Vaccines, Synthetic; C050807:presurface protein 2, hepatitis B surface antigen